Remarkably, treatment of tumor-bearing mice with the targeted RGD4C.PDP-sTRAIL resulted in significant expression of sTRAIL in CS, with approximately a 7.4-fold increase when compared with the non-targeted PDP-sTRAIL group, which showed no detectable expression of sTRAIL in tumors (Figure 7E). The gene discussed is PDP1; the disease is neoplasm.